Market validation for an AI-based solution in DNA design for biomanufacturing

Synthetic biology is advancing biotechnology by enabling precise genetic modifications for enhanced biomanufacturing. At Syngens, we developed a DNA Design Platform by combining artificial intelligence (AI) with synthetic biology to optimize DNA design processes. By employing AI, we replace traditional trial-and-error methods, streamlining the design of microorganisms tailored for specific industrial applications such as biofuel production, enzymes and pharmaceuticals. Traditional DNA design is labor-intensive and imprecise. Integrating AI allows for rapid, accurate predictions of genetic outcomes, speeding up the development of bio-based products and reducing reliance on costly experimental processes. The core of this project has been to validate our AI-driven platform in real-world biomanufacturing settings. Collaborating with industry partners, we demonstrated the platform’s practical utility and efficiency, bridging the gap between research and commercial application. Successful integration of AI into DNA design promises significant advancements in biomanufacturing, contributing to sustainability, economic growth, and global health improvements. By proving the effectiveness of our technology, we pave the way for its broad adoption, marking a leap toward a more sustainable and innovative future in biotechnology.

Se vedlegget.